Seroprevalence of Protective Antibodies Against Influenza and the Reduction of the Influenza Incidence Rate: An Annual Repeated Cross-Sectional Study From 2014 to 2019

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-05-26 DOI:10.1111/irv.13307

Raquel Guiomar, Susana Pereira da Silva, Inês Costa, Patricia Conde, Paula Cristóvão, Ana Paula Rodrigues, Aida Fernandes, Ana Paula Dias, Ana Rita Couto, Angélica Ramos, Carina Moita, Carina Rodrigues, Fátima Vale, Filomena Caldeira, Jácome Bruges Armas, João Pereira-Vaz, José Alves, Ludivina Freitas, Luis Martins, Luís Milho, Luisa Mota-Vieira, Lurdes Lopes, Margarida Freitas, Maria Ana Pessanha, Maria Correia, Maria Helena Marques, Maria João Cardoso, Maria João Peres, Mário Cunha, Patricia Amantegui, Paula Mota, Paulo Lopes, Paulo Pereira, Regina Viseu, Rita Cabral, Rita Côrte-Real, Sofia Almeida, Vânia Soares, Kamal Mansinho, Olav Hungnes, Baltazar Nunes

{"title":"Seroprevalence of Protective Antibodies Against Influenza and the Reduction of the Influenza Incidence Rate: An Annual Repeated Cross-Sectional Study From 2014 to 2019","authors":"Raquel Guiomar, Susana Pereira da Silva, Inês Costa, Patricia Conde, Paula Cristóvão, Ana Paula Rodrigues, Aida Fernandes, Ana Paula Dias, Ana Rita Couto, Angélica Ramos, Carina Moita, Carina Rodrigues, Fátima Vale, Filomena Caldeira, Jácome Bruges Armas, João Pereira-Vaz, José Alves, Ludivina Freitas, Luis Martins, Luís Milho, Luisa Mota-Vieira, Lurdes Lopes, Margarida Freitas, Maria Ana Pessanha, Maria Correia, Maria Helena Marques, Maria João Cardoso, Maria João Peres, Mário Cunha, Patricia Amantegui, Paula Mota, Paulo Lopes, Paulo Pereira, Regina Viseu, Rita Cabral, Rita Côrte-Real, Sofia Almeida, Vânia Soares, Kamal Mansinho, Olav Hungnes, Baltazar Nunes","doi":"10.1111/irv.13307","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Seroepidemiological studies provide estimates of population-level immunity, prevalence/incidence of infections, and evaluation of vaccination programs. We assessed the seroprevalence of protective antibodies against influenza and evaluated the correlation of seroprevalence with the cumulative annual influenza incidence rate.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted an annual repeated cross-sectional seroepidemiological survey, during June–August, from 2014 to 2019, in Portugal. A total of 4326 sera from all age groups, sex, and regions was tested by hemagglutination inhibition assay. Seroprevalence and geometric mean titers (GMT) of protective antibodies against influenza were assessed by age group, sex, and vaccine status (65+ years old). The association between summer annual seroprevalence and the difference of influenza incidence rates between one season and the previous one was measured by Pearson correlation coefficient (<i>r</i>).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Significant differences in seroprevalence of protective antibodies against influenza were observed in the population. Higher seroprevalence and GMT for A(H1N1)pdm09 and A(H3N2) were observed in children (5–14); influenza B seroprevalence in adults 65+ was 1.6–4.4 times than in children (0–4). Vaccinated participants (65+) showed significant higher seroprevalence/GMT for influenza. A strong negative and significant correlation was found between seroprevalence and ILI incidence rate for A(H1N1)pdm09 in children between 5 and 14 (<i>r</i> = −0.84; 95% CI, −0.98 to −0.07); a weak negative correlation was observed for A(H3N2) and B/Yamagata (<i>r</i> ≤ −0.1).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The study provides new insight into the anti-influenza antibodies seroprevalence measured in summer on the ILI incidence rate in the next season and the need for adjusted preventive health care measures to prevent influenza infection and transmission.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13307","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Seroepidemiological studies provide estimates of population-level immunity, prevalence/incidence of infections, and evaluation of vaccination programs. We assessed the seroprevalence of protective antibodies against influenza and evaluated the correlation of seroprevalence with the cumulative annual influenza incidence rate.

Methods

We conducted an annual repeated cross-sectional seroepidemiological survey, during June–August, from 2014 to 2019, in Portugal. A total of 4326 sera from all age groups, sex, and regions was tested by hemagglutination inhibition assay. Seroprevalence and geometric mean titers (GMT) of protective antibodies against influenza were assessed by age group, sex, and vaccine status (65+ years old). The association between summer annual seroprevalence and the difference of influenza incidence rates between one season and the previous one was measured by Pearson correlation coefficient (r).

Results

Significant differences in seroprevalence of protective antibodies against influenza were observed in the population. Higher seroprevalence and GMT for A(H1N1)pdm09 and A(H3N2) were observed in children (5–14); influenza B seroprevalence in adults 65+ was 1.6–4.4 times than in children (0–4). Vaccinated participants (65+) showed significant higher seroprevalence/GMT for influenza. A strong negative and significant correlation was found between seroprevalence and ILI incidence rate for A(H1N1)pdm09 in children between 5 and 14 (r = −0.84; 95% CI, −0.98 to −0.07); a weak negative correlation was observed for A(H3N2) and B/Yamagata (r ≤ −0.1).

Conclusions

The study provides new insight into the anti-influenza antibodies seroprevalence measured in summer on the ILI incidence rate in the next season and the need for adjusted preventive health care measures to prevent influenza infection and transmission.

查看原文本刊更多论文

流感保护性抗体的血清流行率与流感发病率的降低：2014年至2019年年度重复横断面研究》。

背景：血清流行病学研究可估算人群免疫力、感染率/发病率，并对疫苗接种计划进行评估。我们评估了针对流感的保护性抗体的血清流行率，并评估了血清流行率与流感累积年发病率的相关性：方法：我们于2014年至2019年每年6月至8月期间在葡萄牙进行了一次重复性横断面血清流行病学调查。通过血凝抑制试验检测了来自各年龄组、性别和地区的 4 326 份血清。按年龄组、性别和疫苗接种情况（65 岁以上）评估了血清流行率和流感保护性抗体的几何平均滴度（GMT）。用皮尔逊相关系数（r）测量了夏季血清年流行率与上一季度流感发病率差异之间的关系：结果：人群中流感保护性抗体的血清流行率存在显著差异。儿童（5-14 岁）的甲型 H1N1 pdm09 和甲型 H3N2 血清阳性率和格林尼治标准时间均较高；65 岁以上成人的乙型流感血清阳性率是儿童（0-4 岁）的 1.6-4.4 倍。接种疫苗的参与者（65 岁以上）的流感血清流行率/GMT 显著较高。在 5-14 岁儿童中，甲型 H1N1 pdm09 的血清流行率与 ILI 发病率之间存在明显的负相关（r = -0.84; 95% CI, -0.98 to -0.07）；甲型 H3N2 和乙型/山形流感的血清流行率与 ILI 发病率之间存在微弱的负相关（r ≤ -0.1）：该研究为夏季测定的抗流感抗体血清阳性率对下一季流感发病率的影响以及调整预防性保健措施以防止流感感染和传播的必要性提供了新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.